AGBL3 and rheumatoid arthritis: In particular, ~77% of those who developed RA within the Healthfair cohort did not have dual RF-IgA and RF-IgM positivity, and an additional subset with incident RA were negative for both RF’s and/or had anti-CCP3 levels <=60.